ArticlePrecision chemistry2025
Machine-Learning-Assisted Analysis of Patient Clinical Biomarkers to Improve Ovarian Cancer Diagnosis.
Article in Precision chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Precision Chemistry in Precision Diagnostics.Precision chemistry · 2025Article
- Explainable Artificial Intelligence for Ovarian Cancer: Biomarker Contributions in Ensemble Models.Biology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The unavailability of accurate and reliable methods for early ovarian cancer detection represents a major gap in ovarian cancer diagnosis and management. The emergence and recent integration of machine learning with cancer diagnostic techniques, particularly biomarker-based blood tests, have the potential to improve the selectivity and sensitivity of ovarian cancer detection substantially. Herein, we leverage a series of machine learning and statistical approaches to analyze clinically relevant data sets of more than 300 patients with ovarian tumors and 47 blood-obtained features to distinguish between cancerous and benign tumors. We found that HE4, CA125, menopausal status, and age were some of the most important features distinguishing cancerous from benign ovarian tumors in all patient populations. Age was noted to be a critical feature with cancer discriminatory power only in premenopausal patients but less so in postmenopausal patients. Systematic consideration of patient menopausal status, types of machine learning algorithms, and number of clinical features is necessary prior to ovarian cancer screening to yield more accurate and reliable diagnostic results. Overall, this study provides deeper insight into the use of machine learning, feature selection, and other relevant quantitative approaches to advance ovarian cancer diagnosis to improve patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.